SARS-COV-2 ASSOCIATED UVEITIS AND ITS MECHANISM

Abstract

The worldwide COVID-19 pandemic brought about by SARS coronavirus 2 (SARSCoV-2) caught the world by storm, halting back all global operations, and spurred rapid vaccine generation and authorization. From the time of the initial outbreak of the pandemic, 336 vaccine contenders are produced, with 32 vaccines presently approved after rigorous screenings and trials, to be used worldwide. Some of them are BNT162b2 (by Pfizer Inc) and mRNA-1273 (by Moderna) that are mRNA vaccines, Ad26.COV2.S (by Janssen Pharmaceuticals) stimulates an immune response in recipients using a adenovirus type 26 vector, BBV152 COVAXIN (by Bharat Biotech) is a whole virion inactivated vaccine, while COVISHIELD (by Serum Institute of India) is a ChAdOx1-S recombinant vaccine. Given that all the COVID-19 vaccines have been authorized for use in the time of crisis, the Centres for Disease Control and Prevention (CDC) has extended the scope of its Vaccine Adverse Event Reporting System (VAERS) that serves as a means for prior detection of possible vaccine adverse events. Consequently, despite all the careful screening methods, unusual adverse reactions were identified following the administration of different covid vaccines, such as thrombotic thrombocytopenia, Guillain-Barré syndrome, myocarditis, allergy, and many more. One such serious adverse event was an ocular illness, uveitis (a potentially blinding illness that is frequently connected with autoimmune or autoinflammatory diseases). Mechanisms like molecular mimicry, immune complex deposition, immune response against vaccine adjuvant, hyperstimulation of immune system could be the reason behind Vaccine-associated uveitis (VAU). This research thesis focuses on incidence of COVID-19 vaccine associated uveitis and trying to reason its occurrence and finding its possible mechanism.